{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Day One Biopharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"DAWN"},"Address":{"label":"Address","value":"395 OYSTER POINT BOULEVARD,SUITE 217 SUITE 501, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 484-0899"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor."},"CompanyUrl":{"label":"Company Url","value":"https://www.dayonebio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Charles N. York","title":"Chief Operating & Financial Officer, Secretary"},{"name":"Elly Barry","title":"Chief Medical Officer"},{"name":"Jeremy Bender","title":"President, Chief Executive Officer & Director"},{"name":"Mike Pregih","title":"Chief Technology Operations"},{"name":"Samuel C. Blackman","title":"Head-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}